Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Apellis Pharmaceuticals Inc shares valued at $4,572 were sold by Chopas James George on Sep 15 ’25. At $24.19 per share, Chopas James George sold 189 shares. The insider’s holdings dropped to 53,468 shares worth approximately $1.24 million following the completion of this transaction.
Also, Watson David O. purchased 5,000 shares, netting a total of over 121,700 in proceeds.
Before that, Chopas James George had added 189 shares to its account. In a trade valued at $4,572, the Officer bought Apellis Pharmaceuticals Inc shares for $24.19 each.
As published in a research note from Raymond James on May 09, 2025, Apellis Pharmaceuticals Inc [APLS] has been rated down from a Strong buy to an Outperform and the price target has been revised to $52. Analysts at BofA Securities downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in early May. As of April 29, 2025, Cantor Fitzgerald has initiated its “an Overweight” rating for APLS. Earlier on December 17, 2024, Goldman downgraded its rating. Their new recommendation was “a Neutral” for APLS stock which previously was a “a Buy”.
Analyzing APLS Stock Performance
On last trading session, Apellis Pharmaceuticals Inc [NASDAQ: APLS] plunged -2.90% to $23.13. The stock’s lowest price that day was $23.0, but it reached a high of $24.14 in the same session. During the last five days, there has been a drop of approximately -11.18%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -38.52%.
Is Apellis Pharmaceuticals Inc subject to short interest?
Stocks of Apellis Pharmaceuticals Inc saw a sharp steep in short interest on 2025-08-29 dropping by -1.55 million shares to 20.54 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 22.09 million shares. A decline of -7.56% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 7.4 of the overall float, the days-to-cover ratio (short ratio) decline to 7.4.
Which companies own the most shares of Apellis Pharmaceuticals Inc (APLS)?
In terms of Apellis Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 22 in the next 12 months, down nearly -7.64% from the previous closing price of $23.82. Analysts anticipate Apellis Pharmaceuticals Inc stock to reach 22 by 2025, with the lowest price target being 22. In spite of this, 14 analysts ranked Apellis Pharmaceuticals Inc stock as Buy at the end of 2025. On November 21, 2024, Morgan Stanley assigned a price target of “an Equal-weight” to the stock and initiated coverage with a $31.
